Supplemental Table S1. Baseline Characteristics of Participants with and without Incident CVD during Follow-up

Characteristic	Total	CVD		*P* value
		No	Yes	
No. of subjects	981	910 (92.8)	71 (7.2)	
Male sex	563 (57.4)	531 (58.4)	32 (45.1)	0.029
Age, yr	58.4±10.0	58.0±10.0	63.1±9.0	<0.001
BMI, kg/m^2	25.4±3.3	25.4±3.3	25.6±3.1	0.569
Hemoglobin A1c, %	6.8±1.1	6.83±1.1	7.02±0.9	0.070
DM duration, mo	105.0±73.8	103.5±74.6	125.±59.0	0.005
SBP, mm Hg	121.2±13.8	121.0±13.7	123.4±14.4	0.178
DBP, mm Hg	72.2±9.3	72.2±9.3	71.7±9.5	0.673
Hypertension	617 (62.9)	565 (62.1)	52 (73.2)	0.061
Creatinine, mg/dL	1.3±3.7	1.3±3.8	1.0±0.3	0.059
AST, U/L	27.1±15.0	27.1±15.2	27.2±12.1	0.978
ALT, U/L	29.1±20.6	29.3±21.0	27.1±14.7	0.258
TC, mg/dL	166.00±38.1	166.4±38.4	160.2±33.4	0.136
LDL-C, mg/dL	94.0±49.1	94.3±50.5	89.4±23.2	0.127
HDL-C, mg/dL	50.5±12.1	50.6±12.1	49.1±11.2	0.290
UACR, mg/g	34.8±81.2	33.5±81.6	51.1±75.9	0.072
Alcohol consumption[a], drinks/wk				0.255
<10	708 (72.2)	651 (71.5)	57 (80.3)	
≥10	271 (27.6)	257 (28.2)	14 (19.7)	
Current smoker	227 (23.1)	214 (23.5)	13 (18.3)	0.530
Regular exercise[b], times/wk				0.620
<3	680 (69.3)	626 (68.8)	54 (76.1)	
≥3	298 (30.4)	281 (30.9)	17 (23.9)	
Anti-DLP medications	651 (66.4)	603 (66.3)	48 (67.6)	0.810
DM medications				
Metformin	863 (88.0)	800 (87.9)	63 (88.7)	0.838
Sulfonylurea	434 (44.2)	398 (43.7)	36 (50.7)	0.255
Thiazolidinedione	286 (29.2)	276 (30.3)	10 (14.1)	0.004
AGI	124 (12.6)	112 (12.3)	12 (16.9)	0.262
DPP4i	263 (26.8)	243 (26.7)	20 (28.2)	0.788
Insulin	189 (19.3)	163 (17.9)	26 (36.6)	<0.001

Values are expressed as number (%) or mean±standard deviation.

CVD, cardiovascular disease; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; AST, aspartate aminotransferase; ALT, alanine aminotransferase; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; UACR, urinary albumin-to-creatinine ratio; DLP, dyslipidemia; DM, diabetes mellitus; AGI, alpha-glucosidase inhibitor; DPP4i, dipeptidyl peptidase-4 inhibitor.

[a]Alcohol consumption is defined, regardless of sex, as the consumption of >10 standard drinks (140 g) per week; [b]Regular exercise is defined as moderate-intensity exercise lasting more than 1 hour, undertaken three times per week.